Kanamicina sulfat, 2x 6g , ophthalmic ointment
a+
€ 16.90
Composition
100 g of ophthalmic ointment contain kanamycin 1 g in the form of kanamycin sulfate. Yes excipients:
liquid paraffin, solid paraffin, anhydrous lanolin, white Vaseline
Pharmacotherapeutic group: antibiotics for ophthalmic use
Therapeutic indications
Treatment of external infections of the eyeball and appendages produced by germs sensitive to kanamycin: conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcer, blepharitis, blepharoconjunctivitis, dacryocystitis.
Prophylaxis of ophthalmic surgical infections.
Contraindications
Hypersensitivity to kanamycin or to any of the excipients
Precautions
Prolonged local use of antibiotics may increase the resistance of microorganisms.
interaction
Combination with other concomitant aminoglycosides is contraindicated. It is recommended to avoid the association of aminoglycosides, even locally, with polymyxin, cephalothin, furosemide, ethacrynic acid, amphotericin B, cyclosporine, cisplatin or other drugs with nephrotoxic and ototoxic potential (increases the risk of auto- and nephrotoxicity).
Aminoglycoside antibiotics should not be mixed with other drugs, especially beta-lactam antibiotics (in vitro studies have shown that they are mutually inactive).
Special warnings
If no significant therapeutic results have been obtained after a relatively short period of time or if hypersensitivity reactions occur, it is necessary to discontinue treatment and re-evaluate the therapeutic attitude.
In children, the product should be used only if absolutely necessary and under close medical supervision.
Pregnancy and breastfeeding
Although preclinical studies have not shown fetotoxic effects after topical administration of kanamycin, the product is administered during pregnancy only if absolutely necessary and after evaluation of the maternal benefit / potential fetal risk ratio.
As it is not known whether topical kanamycin is excreted in human milk and whether there is a risk of severe adverse reactions in infants, either discontinuation of treatment or discontinuation of breast-feeding should be considered.
Effects on ability to drive and use machines
There is no evidence to suggest that topical administration of kanamycin adversely affects the ability to drive or use machines.
As with other ophthalmic products, transient blurred vision or other visual disturbances may affect the ability to drive or use machines. If transient blurred vision occurs after instillation, the patient should be warned to wait until visual acuity returns to normal before driving or using machines.
Doses and method of administration
KANAMYCIN SULPHATE, ophthalmic ointment: apply in the conjunctival sac 3-4 times a day.
Side effects
KANAMICINE SULPHATE may occasionally cause transient and mild eye irritation. If during treatment there are irritation at the site of application or allergic reactions, treatment should be discontinued.
overdose
Due to the low concentration of the active substance and local administration, acute overdose is unlikely. In case of accidental ingestion, symptomatic treatment is instituted.
storage
Do not use after the expiry date which is stated on the pack.
Do not use after 15 days from the first opening of the tube. Store below 25 ° C in the original package.
Keep out of reach of children.
pack
Box with an aluminum tube of 6 g ophthalmic ointment.
100 g of ophthalmic ointment contain kanamycin 1 g in the form of kanamycin sulfate. Yes excipients:
liquid paraffin, solid paraffin, anhydrous lanolin, white Vaseline
Pharmacotherapeutic group: antibiotics for ophthalmic use
Therapeutic indications
Treatment of external infections of the eyeball and appendages produced by germs sensitive to kanamycin: conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcer, blepharitis, blepharoconjunctivitis, dacryocystitis.
Prophylaxis of ophthalmic surgical infections.
Contraindications
Hypersensitivity to kanamycin or to any of the excipients
Precautions
Prolonged local use of antibiotics may increase the resistance of microorganisms.
interaction
Combination with other concomitant aminoglycosides is contraindicated. It is recommended to avoid the association of aminoglycosides, even locally, with polymyxin, cephalothin, furosemide, ethacrynic acid, amphotericin B, cyclosporine, cisplatin or other drugs with nephrotoxic and ototoxic potential (increases the risk of auto- and nephrotoxicity).
Aminoglycoside antibiotics should not be mixed with other drugs, especially beta-lactam antibiotics (in vitro studies have shown that they are mutually inactive).
Special warnings
If no significant therapeutic results have been obtained after a relatively short period of time or if hypersensitivity reactions occur, it is necessary to discontinue treatment and re-evaluate the therapeutic attitude.
In children, the product should be used only if absolutely necessary and under close medical supervision.
Pregnancy and breastfeeding
Although preclinical studies have not shown fetotoxic effects after topical administration of kanamycin, the product is administered during pregnancy only if absolutely necessary and after evaluation of the maternal benefit / potential fetal risk ratio.
As it is not known whether topical kanamycin is excreted in human milk and whether there is a risk of severe adverse reactions in infants, either discontinuation of treatment or discontinuation of breast-feeding should be considered.
Effects on ability to drive and use machines
There is no evidence to suggest that topical administration of kanamycin adversely affects the ability to drive or use machines.
As with other ophthalmic products, transient blurred vision or other visual disturbances may affect the ability to drive or use machines. If transient blurred vision occurs after instillation, the patient should be warned to wait until visual acuity returns to normal before driving or using machines.
Doses and method of administration
KANAMYCIN SULPHATE, ophthalmic ointment: apply in the conjunctival sac 3-4 times a day.
Side effects
KANAMICINE SULPHATE may occasionally cause transient and mild eye irritation. If during treatment there are irritation at the site of application or allergic reactions, treatment should be discontinued.
overdose
Due to the low concentration of the active substance and local administration, acute overdose is unlikely. In case of accidental ingestion, symptomatic treatment is instituted.
storage
Do not use after the expiry date which is stated on the pack.
Do not use after 15 days from the first opening of the tube. Store below 25 ° C in the original package.
Keep out of reach of children.
pack
Box with an aluminum tube of 6 g ophthalmic ointment.